Mosaic chromosomal aberrations in synovial fibroblasts of patients with rheumatoid arthritis, osteoarthritis, and other inflammatory joint diseases

Supplementary Table 1 Clinical characteristics of the subjects at the time of synovectomy/sampling

Subjects (n)	Gender (M/F)	Age (years)	Disease duration (years)	RF (+/-)	ESR (mm/h)	CRP^a (mg/l)	No. of ARA criteria (RA)	Concomitant medication (n)
Rheumatoid arthritis
21	10/11	63.1 ± 2.0	10.7 ± 2.1 (n.d. = 1)	14/4 (n.d. = 3)	36.6 ± 5.2 (n.d. = 3)	41.4 ± 7.8 (n.d. = 1)	5.1 ± 0.2	Methotrexate (10), Prednisolone (16), Sulfasalazine (4), Gold salts (1), NSAIDs (14)
Osteoarthritis
24	5/19	69.5 ± 2.3	9.3 ± 3.0 (n.d. = 15)	0/6 (n.d. = 18)	18.4 ± 3.7 (n.d. = 2)	6.4 ± 1.1 (n.d. = 1)	0.3 ± 0.1	Prednisolone(1), NSAIDs (11), none (13)
Spondylarthropathy
3	3/0	37.0 ± 12.5	3.8 ± 3.1	0/3	22.3 ± 12.8	24.4 ± 19.4	1.0 ± 1.0	Sulfasalazine (1), NSAIDs (2), none (1)
Other arthritides
L02 / VNS	F	64	4	-	18	<5	0	Methotrexate, NSAIDs
L04 / SLE	F	38	7	-	11	28.9	3	Methotrexate, Prednisolone
ES36 / JRA	M	18	14	-	4	<5	2	Chloroquine, NSAIDs
ES63 / UA	M	18	1	-	2	<5	0	NSAIDs
EB32 / ReA	M	43	8	n.d.	60	8.5	1	none
Joint trauma/normals
4	2/2	49.3 ± 9.5	0.5 ± 0.5	n.d.	n.d.	n.d.	0.0 ± 0.0	none (4)
Normal skin
4	1/3	20.3 ± 10.7	0.0 ± 0.0	n.d.	n.d.	n.d.	0.0 ± 0.0	none (4)

^aNormal range, <5 mg/l. +/- = positive/negative; ARA = American Rheumatism Association (now American College of Rheumatology); AS = ankylosing spondylitis; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; JRA = juvenile rheumatoid arthritis; n.d. = not determined; NSAIDs = nonsteroidal anti-inflammatory drugs. RA = rheumatoid arthritis; ReA = reactive arthritis; RF = rheumatoid factor; SLE = systemic lupus erythematosus; UA = undifferentiated monoarthritis; VNS = villonodular synovitis. For the parameters age, disease duration, ESR, CRP, and number of ARA-Criteria (RA), values are means ± SEM; for the other parameters, values are numbers (n).

ISSN: 1478-6362